SOPHiA GENETICS' partnership with Ankara Etlik City Hospital, the largest hospital in Turkey's capital, is a significant milestone for the company. The hospital's adoption of the SOPHiA DDM™ Platform for genomic testing will likely increase the company's visibility and credibility in the healthcare sector, potentially leading to more partnerships and increased revenue. This positive news is expected to have a short-term positive impact on SOPH's stock price.